How Does Wegovy Actually Work? The Mechanism, Explained

How does Wegovy actually work?

Semaglutide, the drug in Wegovy, is a GLP-1 receptor agonist — a lab-made version of glucagon-like peptide-1, a hormone your gut already releases in small amounts after you eat. Natural GLP-1 fades within minutes. Semaglutide is engineered to persist for about a week per dose, which turns a fleeting after-meal signal into a sustained one your body responds to all week long.

That sustained signal does three things at once, and none of them involve burning fat directly:

• Slows gastric emptying — food sits in your stomach longer, so fullness after a meal lasts longer too
• Acts on appetite centers in the hypothalamus — turns down hunger signals and, for many people, quiets the background noise around food, not just physical hunger
• Triggers insulin release only when blood sugar is already elevated, and lowers how much glucagon your body releases at the same time — the reason it doesn't tend to cause the blood-sugar crashes some other medications do

Put together, weight loss on Wegovy is a downstream effect of eating less over time, not a metabolic furnace turned up. That distinction matters because it explains why results plateau once your eating pattern stabilizes, and why appetite tends to drift back afterward if the medication stops — the signal was doing the work, and removing it removes the signal.

What is Wegovy actually approved to treat?

Wegovy now carries three separate FDA approvals, and the list has grown since it first launched. The original 2021 approval is for chronic weight management — reducing and maintaining lower body weight in adults with obesity, or with overweight plus at least one weight-related condition such as high blood pressure or high cholesterol, alongside a reduced-calorie diet and more physical activity. A second approval, added in 2024 after the SELECT cardiovascular outcomes trial, covers reducing the risk of major cardiovascular events — heart attack, stroke, cardiovascular death — in adults with established heart disease who also have obesity or overweight.

The newest one is less well known: in 2025, the FDA granted accelerated approval for Wegovy to treat noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced liver fibrosis — a serious fatty liver disease, treated before it progresses to cirrhosis. It's the first GLP-1 medication to carry a liver-disease indication, on top of weight management and cardiovascular risk reduction. Ozempic, the same molecule at a lower maximum dose, has none of these three approvals — it's approved only for type 2 diabetes, which is the detail that trips up almost everyone comparing the two.

Why would a 45-year-old without diabetes be prescribed this?

Because Wegovy's actual approval was never about blood sugar. The eligibility criteria are a BMI of 30 or higher, or 27 or higher with a weight-related condition like high blood pressure, high cholesterol, or sleep apnea — diabetes isn't a requirement anywhere on that list. A woman in perimenopause who meets that threshold is being prescribed Wegovy for exactly what it was built and approved to treat, not an off-label workaround the way Ozempic-for-weight-loss is.

There's also a reason this comes up more often in your 40s and 50s specifically. Declining, fluctuating estrogen tends to redirect fat storage toward the abdomen, dulls insulin sensitivity, and shifts resting metabolism — changes that can push someone across the BMI or comorbidity threshold for the first time in midlife, independent of anything she's doing differently. The mechanism itself doesn't change based on reproductive stage, but the body it's acting on often does. Our GLP-1 and menopause guide goes further into how that overlap actually plays out.

Is Wegovy just Ozempic at a higher dose?

Mechanically, yes — chemically, it's the identical molecule, semaglutide. What separates them is dose ceiling and approval, not the drug itself. Ozempic tops out at 2mg weekly and is approved only for type 2 diabetes; Wegovy climbs to 2.4mg standard (with a newer 7.2mg step-up option for people who've plateaued), and carries the weight-management, cardiovascular, and MASH approvals described above. Using Ozempic for weight loss is real, common, and often effective — but it's off-label, borrowing its safety and efficacy reasoning from Wegovy's own trial data rather than dedicated trials of its own. How Ozempic actually works, and on what timeline, covers that off-label picture and the week-by-week curve in more depth than fits here.

How is Wegovy different from Zepbound?

Here the molecule itself changes, not just the dose. Zepbound's active ingredient is tirzepatide, an entirely different drug from semaglutide. Where Wegovy acts on one receptor — GLP-1 — tirzepatide is engineered to act on two: it activates the GLP-1 receptor and the GIP receptor (glucose-dependent insulinotropic polypeptide) at the same time, with a particularly strong pull on the GIP side. GIP is a second gut hormone involved in insulin release and fat metabolism, and combining the two signals appears to produce a stronger appetite and metabolic effect than working the GLP-1 receptor alone.

That shows up in the trial data: in the first head-to-head trial between the two drugs, tirzepatide produced a larger average weight loss than semaglutide at 72 weeks — roughly 20% of body weight versus about 14%. That's a real, meaningful gap, though it's not the whole decision — cost, tolerability, and how your particular body responds to each drug matter just as much as the trial average. Wegovy vs. Zepbound breaks down the full efficacy-versus-cost picture if you're actively weighing the two.

How fast do you actually feel any of this?

Semaglutide reaches peak blood levels within a day or two of a first injection, but the earliest doses on the ladder are deliberately too low to produce much of an appetite effect — their job is letting your gut adjust, not doing the treatment work yet. Appetite is usually the first thing to shift, often within the first couple of weeks, as the dose climbs. The specific week-by-week schedule and starting numbers live in the Wegovy dosage chart; what typically changes about eating day to day, and where alcohol and food choices fit in, is covered in the Wegovy diet guide.

Does anything about the mechanism change once perimenopause is part of the picture?

The receptor biology doesn't change — GLP-1 receptors respond the same way regardless of reproductive stage. What changes is the starting conditions the drug is working against. A slower resting metabolism, fat that's already shifted toward the abdomen, and declining muscle mass are all things perimenopause tends to bring on independently of any medication, and none of them stop semaglutide from working — they just mean the baseline looks different than it would for a younger patient on the identical prescription.

One mechanism-adjacent detail worth knowing going in: because appetite suppression affects what you eat generally, not selectively, a meaningful share of the weight GLP-1 medications remove is lean muscle, not only fat — more consequential in your 40s and 50s, when estrogen decline is already working against muscle on its own. That's a reason to pair the prescription with protein and resistance training, not a reason to avoid it. GLP-1 and muscle loss in perimenopause covers the mechanism and what actually protects muscle during treatment. For what the medication does to your body beyond the mechanism — the common adjustment-period effects, and what's actually serious — see Wegovy side effects.